Aurora Spine Corporation announced it has received Institutional Review Board (IRB) multi-site selection approval for its new multicenter study of DEXA-C™ Cervical Interbody System. The study has selected seven sites with three submitted for approval. After approval, patient enrollment is expected to begin.

The study will initially include data from 40 single level and 40 multiple level subjects. The DEXA-C system is indicated for anterior cervical interbody fusion procedures and is the first in a series of implants based on Aurora's patented DEXA™ technology platform. Based on the DEXA T-score for measuring a patient's bone density, the DEXA technology platform includes implants that are of varying densities to match a patient's bone density.

DEXA-C is intended for use on patients who require anterior cervical discectomy and fusion surgery. The DEXA-C system implants an interbody spacer into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment are fixed with an anterior cervical plate.

The secondary outcome measures will include subsidence and alignment assessments. Patient reported outcomes (NDI and VAS) will be collected at follow up visits and assessed compared to baseline.